Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs

Takuya Tsuchihashi, Michio Ueno, Mitsuhiro Tominaga, Tomoko Kajioka, Uran Onaka, Kenichi Goto, Yuko Ohta, Kimika Eto

研究成果: ジャーナルへの寄稿記事

抄録

We investigated the long-term antiproteinuric effect of an L/N-type calcium channel (Ca) blocker, cilnidipine in the patients with essential hypertension (EHT). Subjects are 37 EHT patients (61±2 (SE) years, 22 females and 15 males). All patients underwent 24-h home urine collection and proved to have proteinuria greater than 0.1 g/day. Cilnidipine at a mean dose of 8 mg was administered to the patients. In 30 patients, cilnidipine was switched from other Ca antagonists including manidipine and amlodipine, while cilnidipine was newly added in the other 7 patients. Seventeen patients have been received either ACE inhibitors (ACEI) or ARBs at least 6 months before the administration of cilnidipine. Blood pressure (BP), blood chemistry and 24-h home urine collection were determined at 6, 12 and 24 months after the administration of cilnidipine. Baseline BP was 142±2/85±1 mmHg. Systolic BP did not change significantly throughout the study, while diastolic BP was significantly lower at 6 months (82±1 mmHg, p < 0.01), 12 months (84±1 mmHg, p < 0.05) and 24 months (82±2 mmHg, p < 0.05). Urinary protein excretion decreased significantly from 0.36±0.04 g/day to 0.16±0.02 g/day(-45.7±6.7%, p < 0.01) at 6 months and to 0.14±0.04 g/day (-57.8±12.0%, p < 0.01) at 12 months. The reduction of proteinuria occurred independently of the changes in BP. Urinary salt excretion, estimated protein intake, and serum creatinine concentration did not change significantly during the observation period. The reduction of proteinuria at 6 months after cilnidipine was similar between the patients with the baseline administration of ACEI/ARB (-47.6±11.2%, p < 0.01) and those without ACEI/ARB (-44.4±8.7%, p < 0.01). On the other hand, the reduction of proteinuria continued until 24 months in the patients with ACEI/ARB (-41.1±16.3%, p < 0.05) but not in those without ACEI/ARB (-9.3 ±49.1%, ns). Results suggest that cilnidipine exerts antiproteinuric effect irrespectively of the co-administration of ACEI/ARB. However, the effect of cilnidipine may last longer in the presence of ACEI/ARB.

元の言語英語
ページ(範囲)1597-1603
ページ数7
ジャーナルTherapeutic Research
27
発行部数8
出版物ステータス出版済み - 2006
外部発表Yes

Fingerprint

N-Type Calcium Channels
L-Type Calcium Channels
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Proteinuria
Urine Specimen Collection
Therapeutics
manidipine
cilnidipine
Amlodipine
Blood Proteins
Creatinine
Salts
Observation

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs. / Tsuchihashi, Takuya; Ueno, Michio; Tominaga, Mitsuhiro; Kajioka, Tomoko; Onaka, Uran; Goto, Kenichi; Ohta, Yuko; Eto, Kimika.

:: Therapeutic Research, 巻 27, 番号 8, 2006, p. 1597-1603.

研究成果: ジャーナルへの寄稿記事

Tsuchihashi, T, Ueno, M, Tominaga, M, Kajioka, T, Onaka, U, Goto, K, Ohta, Y & Eto, K 2006, 'Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs', Therapeutic Research, 巻. 27, 番号 8, pp. 1597-1603.
Tsuchihashi, Takuya ; Ueno, Michio ; Tominaga, Mitsuhiro ; Kajioka, Tomoko ; Onaka, Uran ; Goto, Kenichi ; Ohta, Yuko ; Eto, Kimika. / Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs. :: Therapeutic Research. 2006 ; 巻 27, 番号 8. pp. 1597-1603.
@article{ff774ddfed1d495ab957e5e53faa4d2e,
title = "Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs",
abstract = "We investigated the long-term antiproteinuric effect of an L/N-type calcium channel (Ca) blocker, cilnidipine in the patients with essential hypertension (EHT). Subjects are 37 EHT patients (61±2 (SE) years, 22 females and 15 males). All patients underwent 24-h home urine collection and proved to have proteinuria greater than 0.1 g/day. Cilnidipine at a mean dose of 8 mg was administered to the patients. In 30 patients, cilnidipine was switched from other Ca antagonists including manidipine and amlodipine, while cilnidipine was newly added in the other 7 patients. Seventeen patients have been received either ACE inhibitors (ACEI) or ARBs at least 6 months before the administration of cilnidipine. Blood pressure (BP), blood chemistry and 24-h home urine collection were determined at 6, 12 and 24 months after the administration of cilnidipine. Baseline BP was 142±2/85±1 mmHg. Systolic BP did not change significantly throughout the study, while diastolic BP was significantly lower at 6 months (82±1 mmHg, p < 0.01), 12 months (84±1 mmHg, p < 0.05) and 24 months (82±2 mmHg, p < 0.05). Urinary protein excretion decreased significantly from 0.36±0.04 g/day to 0.16±0.02 g/day(-45.7±6.7{\%}, p < 0.01) at 6 months and to 0.14±0.04 g/day (-57.8±12.0{\%}, p < 0.01) at 12 months. The reduction of proteinuria occurred independently of the changes in BP. Urinary salt excretion, estimated protein intake, and serum creatinine concentration did not change significantly during the observation period. The reduction of proteinuria at 6 months after cilnidipine was similar between the patients with the baseline administration of ACEI/ARB (-47.6±11.2{\%}, p < 0.01) and those without ACEI/ARB (-44.4±8.7{\%}, p < 0.01). On the other hand, the reduction of proteinuria continued until 24 months in the patients with ACEI/ARB (-41.1±16.3{\%}, p < 0.05) but not in those without ACEI/ARB (-9.3 ±49.1{\%}, ns). Results suggest that cilnidipine exerts antiproteinuric effect irrespectively of the co-administration of ACEI/ARB. However, the effect of cilnidipine may last longer in the presence of ACEI/ARB.",
author = "Takuya Tsuchihashi and Michio Ueno and Mitsuhiro Tominaga and Tomoko Kajioka and Uran Onaka and Kenichi Goto and Yuko Ohta and Kimika Eto",
year = "2006",
language = "English",
volume = "27",
pages = "1597--1603",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "8",

}

TY - JOUR

T1 - Antiproteinuric effect of an L/N-type calcium channel blocker, cilnidipine, with special reference to the combination therapy with ACE inhibitors or ARBs

AU - Tsuchihashi, Takuya

AU - Ueno, Michio

AU - Tominaga, Mitsuhiro

AU - Kajioka, Tomoko

AU - Onaka, Uran

AU - Goto, Kenichi

AU - Ohta, Yuko

AU - Eto, Kimika

PY - 2006

Y1 - 2006

N2 - We investigated the long-term antiproteinuric effect of an L/N-type calcium channel (Ca) blocker, cilnidipine in the patients with essential hypertension (EHT). Subjects are 37 EHT patients (61±2 (SE) years, 22 females and 15 males). All patients underwent 24-h home urine collection and proved to have proteinuria greater than 0.1 g/day. Cilnidipine at a mean dose of 8 mg was administered to the patients. In 30 patients, cilnidipine was switched from other Ca antagonists including manidipine and amlodipine, while cilnidipine was newly added in the other 7 patients. Seventeen patients have been received either ACE inhibitors (ACEI) or ARBs at least 6 months before the administration of cilnidipine. Blood pressure (BP), blood chemistry and 24-h home urine collection were determined at 6, 12 and 24 months after the administration of cilnidipine. Baseline BP was 142±2/85±1 mmHg. Systolic BP did not change significantly throughout the study, while diastolic BP was significantly lower at 6 months (82±1 mmHg, p < 0.01), 12 months (84±1 mmHg, p < 0.05) and 24 months (82±2 mmHg, p < 0.05). Urinary protein excretion decreased significantly from 0.36±0.04 g/day to 0.16±0.02 g/day(-45.7±6.7%, p < 0.01) at 6 months and to 0.14±0.04 g/day (-57.8±12.0%, p < 0.01) at 12 months. The reduction of proteinuria occurred independently of the changes in BP. Urinary salt excretion, estimated protein intake, and serum creatinine concentration did not change significantly during the observation period. The reduction of proteinuria at 6 months after cilnidipine was similar between the patients with the baseline administration of ACEI/ARB (-47.6±11.2%, p < 0.01) and those without ACEI/ARB (-44.4±8.7%, p < 0.01). On the other hand, the reduction of proteinuria continued until 24 months in the patients with ACEI/ARB (-41.1±16.3%, p < 0.05) but not in those without ACEI/ARB (-9.3 ±49.1%, ns). Results suggest that cilnidipine exerts antiproteinuric effect irrespectively of the co-administration of ACEI/ARB. However, the effect of cilnidipine may last longer in the presence of ACEI/ARB.

AB - We investigated the long-term antiproteinuric effect of an L/N-type calcium channel (Ca) blocker, cilnidipine in the patients with essential hypertension (EHT). Subjects are 37 EHT patients (61±2 (SE) years, 22 females and 15 males). All patients underwent 24-h home urine collection and proved to have proteinuria greater than 0.1 g/day. Cilnidipine at a mean dose of 8 mg was administered to the patients. In 30 patients, cilnidipine was switched from other Ca antagonists including manidipine and amlodipine, while cilnidipine was newly added in the other 7 patients. Seventeen patients have been received either ACE inhibitors (ACEI) or ARBs at least 6 months before the administration of cilnidipine. Blood pressure (BP), blood chemistry and 24-h home urine collection were determined at 6, 12 and 24 months after the administration of cilnidipine. Baseline BP was 142±2/85±1 mmHg. Systolic BP did not change significantly throughout the study, while diastolic BP was significantly lower at 6 months (82±1 mmHg, p < 0.01), 12 months (84±1 mmHg, p < 0.05) and 24 months (82±2 mmHg, p < 0.05). Urinary protein excretion decreased significantly from 0.36±0.04 g/day to 0.16±0.02 g/day(-45.7±6.7%, p < 0.01) at 6 months and to 0.14±0.04 g/day (-57.8±12.0%, p < 0.01) at 12 months. The reduction of proteinuria occurred independently of the changes in BP. Urinary salt excretion, estimated protein intake, and serum creatinine concentration did not change significantly during the observation period. The reduction of proteinuria at 6 months after cilnidipine was similar between the patients with the baseline administration of ACEI/ARB (-47.6±11.2%, p < 0.01) and those without ACEI/ARB (-44.4±8.7%, p < 0.01). On the other hand, the reduction of proteinuria continued until 24 months in the patients with ACEI/ARB (-41.1±16.3%, p < 0.05) but not in those without ACEI/ARB (-9.3 ±49.1%, ns). Results suggest that cilnidipine exerts antiproteinuric effect irrespectively of the co-administration of ACEI/ARB. However, the effect of cilnidipine may last longer in the presence of ACEI/ARB.

UR - http://www.scopus.com/inward/record.url?scp=33750291305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750291305&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750291305

VL - 27

SP - 1597

EP - 1603

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 8

ER -